- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Children (1-11 years)
- Adolescents (12-17 years)
- Community
- SARS-CoV-2
- Influenza-like illness/Acute respiratory infection
Setting: Community
A research environment where studies are conducted outside of clinical or laboratory settings, focusing on real-world populations
- General population
- Infants (<1 year)
- Children (1-11 years)
- Community
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Adenovirus
- Rhinovirus
- Human metapneumovirus
- Parainfluenza Virus
- Enterovirus
- Seasonal coronavirus
- Bocavirus
- Influenza-like illness/Acute respiratory infection
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Children (1-11 years)
- Adolescents (12-17 years)
- Community
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Influenza-like illness/Acute respiratory infection
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Community
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Adenovirus
- Influenza-like illness/Acute respiratory infection
- Diagnostics
- Point of care tests
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Infants (<1 year)
- Children (1-11 years)
- Adolescents (12-17 years)
- Community
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- Influenza-like illness/Acute respiratory infection
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Infants (<1 year)
- Children (1-11 years)
- Adolescents (12-17 years)
- Community
- Influenza-like illness/Acute respiratory infection
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Community
- Hantavirus
- Puumala virus
- General population
- Infants (<1 year)
- Children (1-11 years)
- Adolescents (12-17 years)
- Community
- Household
- SARS-CoV-2
- Respiratory syncytial virus
- Influenza virus
- General population
- Infants (<1 year)
- Community
- Respiratory syncytial virus
- Pharmacological intervention
- Monoclonal antibodies
- Nirsevimab
- Adults (18-64 years)
- General population
- Elderly (≥65 years)
- Children (1-11 years)
- Adolescents (12-17 years)
- Community
- Monkeypox virus
- Adults (18-64 years)
- General population
- Community
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Colchicine
- Antihistamines
- Rivaroxaban
- Adults (18-64 years)
- Outpatient clinic
- Community
- Primary care
- SARS-CoV-2
- Post COVID-19 condition
- Post-acute infection syndrome
- Pharmacological intervention
- Immunomodulator
- Colchicine
- Metformin